Alan Mendelsohn Biography and Net Worth

Insider of Timber Pharmaceuticals

Alan Mendelsohn holds the position of Chief Medical Officer & Executive Vice President at Timber Pharmaceuticals, Inc.

In the past Dr. Mendelsohn held the position of Senior Director-Immunology Research & Development at Johnson & Johnson and Associate VP-Dermatology Medical Affairs at Sun Pharmaceutical Industries Ltd.

He received a doctorate from State University of New York at Downstate Medical Center.

How old is Alan Mendelsohn?: Dr. Mendelsohn is currently 60 years old. There are 2 older executives and no younger executives at Timber Pharmaceuticals. Learn More on Alan Mendelsohn's age.
How do I contact Alan Mendelsohn?: The corporate mailing address for Dr. Mendelsohn and other Timber Pharmaceuticals executives is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. Timber Pharmaceuticals can also be reached via phone at (973) 314-9577 and via email at [email protected]. Learn More on Alan Mendelsohn's contact information.
Has Alan Mendelsohn been buying or selling shares of Timber Pharmaceuticals?: Alan Mendelsohn has not been actively trading shares of Timber Pharmaceuticals within the last three months. Most recently, on Tuesday, November 23rd, Alan Mendelsohn bought 10,000 shares of Timber Pharmaceuticals stock. The stock was acquired at an average cost of $0.47 per share, with a total value of $4,700.00. Learn More on Alan Mendelsohn's trading history.
Who are Timber Pharmaceuticals' active insiders?: Timber Pharmaceuticals' insider roster includes John Koconis (CEO), Alan Mendelsohn (Insider), and Edward Sitar (Director). Learn More on Timber Pharmaceuticals' active insiders.

Alan Mendelsohn Insider Trading History at Timber Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/23/2021	Buy	10,000	$0.47	$4,700.00

Alan Mendelsohn Buying and Selling Activity at Timber Pharmaceuticals

Timber Pharmaceuticals Company Overview

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

Today's Range

Now: N/A

50 Day Range

MA: $1.87

$0.34

$2.94

2 Week Range

Now: N/A

Volume

26,307 shs

Average Volume

511,937 shs

Market Capitalization

$1.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.